China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 115.5% in January

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 7,347,822 shares, a growth of 115.5% from the January 15th total of 3,408,880 shares. Based on an average daily volume of 35,892,593 shares, the days-to-cover ratio is presently 0.2 days. Currently, 794.4% of the shares of the company are short sold. Currently, 794.4% of the shares of the company are short sold. Based on an average daily volume of 35,892,593 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, February 7th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, China SXT Pharmaceuticals currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in China SXT Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 48,759 shares of the company’s stock, valued at approximately $78,000. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Price Performance

Shares of NASDAQ:SXTC remained flat at $2.49 during midday trading on Thursday. The stock had a trading volume of 21,566 shares, compared to its average volume of 558,768. China SXT Pharmaceuticals has a fifty-two week low of $2.34 and a fifty-two week high of $1,176.00. The firm has a fifty day simple moving average of $124.09 and a 200 day simple moving average of $192.15.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.